Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives

References

• Li S-S, Lian Y-F, Huang Y-L, et al. Overexpressing PLOD family genes predict poor prognosis in gastric cancer. J Cancer 2020;11:121–31.
   PubMed Web of Science ®Google Scholar
• Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 2020;20:74–88.
   PubMed Web of Science ®Google Scholar
• Li Z, You Q, Zhang X. Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem 2019;62:5725–49.
   PubMed Web of Science ®Google Scholar
• Ferreira BI, Lie MK, Engelsen AST, et al. Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm 2017;8:53–66.
   PubMed Web of Science ®Google Scholar
• Krzykawska-Serda M, Miller RC, Elas M, et al. Correlation between hypoxia proteins and EPR-detected hypoxia in tumors. Adv Exp med Biol 2017;977:319–325.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci China Life Sci 2017;60:1114–24.
   PubMed Web of Science ®Google Scholar
• Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol 2020;21:268–83.
   PubMed Web of Science ®Google Scholar
• Xu D, Li DW, Xie J, et al. Effect and mechanism of survivin on hypoxia-induced multidrug resistance of human laryngeal carcinoma cells. BioMed Res Int 2019;2019:1–6.
   Web of Science ®Google Scholar
• Saleh R, Taha RZ, Nair VS, et al. PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer. Cancers 2019;11:1050.
   PubMed Web of Science ®Google Scholar
• Maruggi M, Layng FI, Lemos R, Jr., et al. Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth. Cancer Res 2019;79:5839–48.
   PubMed Web of Science ®Google Scholar
• Chipurupalli S, Kannan E, Tergaonkar V, et al. Hypoxia induced ER stress response as an adaptive mechanism in cancer. Int J Mol Sci 2019;20:749.
   Web of Science ®Google Scholar
• Sanfilippo R, Jones RL, Blay J-Y, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas). Clin Cancer Res 2019;25:5295–300.
   PubMed Web of Science ®Google Scholar
• Saxenaa AK, Bhuniab SS. Development of VEGFR inhibitors as antiangiogenic agents. Med Chem Rev 2016;51:297–310.
   Google Scholar
• Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol 2016;7:428–38.
   PubMed Web of Science ®Google Scholar
• Paiva TF, Fonseca de Jesus VH, Marques RA, et al. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015;15:643–12.
   PubMed Web of Science ®Google Scholar
• Mishra GP, Doddapaneni BS, Nguyen D, et al. Antiangiogenic effect of docetaxel and everolimus as individual and dual-drug-loaded micellar nanocarriers. Pharm Res 2014;31:660–9.
   PubMed Web of Science ®Google Scholar
• Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923–30.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.
   PubMed Web of Science ®Google Scholar
• Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008;283:30766–71.
   PubMed Web of Science ®Google Scholar
• Duda DM, Tu C, Fisher SZ, et al. Human carbonic anhydrase III: structural and kinetic study of catalysis and proton transfer. Biochemistry 2005;44:10046–53.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Op Therap Patents 2018;28:729–40.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Winum JY. Carbonic anhydrase IX inhibitors in cancer therapy: an update. Future Med Chem 2015;7:1407–14.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World J Clin Oncol 2012;3:98–103.
   PubMedGoogle Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Rev Drug Disc 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2010;1804:404–9.
   PubMed Web of Science ®Google Scholar
• Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metast Rev 2007;26:299–310.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Zavada J. Tumor‐associated carbonic anhydrases and their clinical significance. Adv Clin Chem. 2006;42:167–216.
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48:4834–41.
   PubMed Web of Science ®Google Scholar
• Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013;13:611–23.
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites 2020;10:412.
   PubMed Web of Science ®Google Scholar
• Melis C, Distinto S, Bianco G, et al. Targeting tumor associated carbonic anhydrases IX and XII: highly isozyme selective coumarin and psoralen inhibitors. ACS Med Chem Lett 2018;9:725–9.
   PubMed Web of Science ®Google Scholar
• Fois B, Distinto S, Meleddu R, et al. Coumarins from Magydaris pastinacea as inhibitors of the tumour-associated carbonic anhydrases IX and XII: isolation, biological studies and in silico evaluation. J Enzyme Inhibition Med Chem 2020;35:539–48.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Coumarin carbonic anhydrase inhibitors from natural sources. J Enzyme Inhibition Med Chem 2020;35:1462–70.
   PubMed Web of Science ®Google Scholar
• Mancuso F, De Luca L, Angeli A, et al. Synthesis, computational studies and assessment of in vitro inhibitory activity of umbelliferon-based compounds against tumour-associated carbonic anhydrase isoforms IX and XII. J Enzyme Inhibition Med Chem 2020;35:1442–9.
   PubMed Web of Science ®Google Scholar
• De Luca L, Mancuso F, Ferro S, et al. Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases. Euro J Med Chem 2018;143:276–82.
   PubMed Web of Science ®Google Scholar
• Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010;53:850–4.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62.
   PubMed Web of Science ®Google Scholar
• Cozza G, Gianoncelli A, Bonvini P, et al. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors. ChemMedChem 2011;6:2273–86.
   PubMed Web of Science ®Google Scholar
• Yang EB, Zhao YN, Zhang K, et al. Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor. Biochem Biophys Res Commun 1999;260:682–5.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Y, Sharma A, et al. Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR signaling. Anti-Cancer Drugs 2015;26:667–77.
   PubMed Web of Science ®Google Scholar
• Mi C, Ma J, Wang KS, et al. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways. J Ethnopharmacol 2017;203:27–38.
   PubMed Web of Science ®Google Scholar
• Park H, Choe H, Hong S. Virtual screening and biochemical evaluation to identify new inhibitors of mammalian target of rapamycin (mTOR). Bioorg Med Chem Lett 2014;24:835–8.
   PubMedGoogle Scholar
• Wu Y, Xu J, Liu Y, et al. A review on anti-tumor mechanisms of coumarins. Front Oncol 2020;10:592853.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• Berrino E, Angeli A, Zhdanov DD, et al. Azidothymidine “Clicked” into 1,2,3-triazoles: first report on carbonic anhydrase-telomerase dual-hybrid inhibitors. J Med Chem 2020;63:7392–409.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902.
   PubMed Web of Science ®Google Scholar
• Bilginer S, Gonder B, Gul HI, et al. Novel sulphonamides incorporating triazene moieties show powerful carbonic anhydrase I and II inhibitory properties. J Enzyme Inhibition Medi Chem 2020;35:325–9.
   PubMed Web of Science ®Google Scholar
• Schrödinger LLC.: New York N, USA, 2018.
   Google Scholar
• Mohamadi F, Richards NGJ, Guida WC, et al. Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990;11:440–67.
   Web of Science ®Google Scholar
• Halgren TA. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem 1996;17:520–52.
   Web of Science ®Google Scholar
• Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889–97.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar
• Behnke CA, Le Trong I, Godden JW, et al. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr Sect D, Biol Crystallogr 2010;66:616–27.
   PubMedGoogle Scholar
• Leitans J, Kazaks A, Balode A, et al. Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX. J Med Chem 2015;58:9004–9.
   PubMed Web of Science ®Google Scholar
• Chung JY, Hah JM, Cho AE. Correlation between performance of QM/MM docking and simple classification of binding sites. J Chem Info Model 2009;49:2382–7.
   PubMed Web of Science ®Google Scholar
• Schrödinger LLC. The PyMOL molecular graphics system. Version 1.7. New York (NY): Schrödinger LLC.
   Google Scholar
• Meleddu R, Petrikaite V, Distinto S, et al. Investigating the anticancer activity of isatin/dihydropyrazole hybrids. ACS Med Chem Lett 2019;10:571–6.
   PubMed Web of Science ®Google Scholar
• Meleddu R, Distinto S, Cottiglia F, et al. Tuning the dual inhibition of carbonic anhydrase and cyclooxygenase by dihydrothiazole benzensulfonamides. ACS Med Chem Lett 2018;9:1045–50.
   PubMed Web of Science ®Google Scholar
• Melis C, Meleddu R, Angeli A, et al. Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2017;32:68–73.
   PubMed Web of Science ®Google Scholar
• Bianco G, Meleddu R, Distinto S, et al. N-acylbenzenesulfonamide dihydro-1,3,4-oxadiazole hybrids: seeking selectivity toward carbonic anhydrase isoforms. ACS Med Chem Lett 2017;8:792–6.
   PubMed Web of Science ®Google Scholar
• Meleddu R, Maccioni E, Distinto S, et al. New 4-[(3-cyclohexyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulfonamides, synthesis and inhibitory activity toward carbonic anhydrase I, II, IX, XII. Bioorg Med Chem Lett 2015;25:3281–4.
   PubMed Web of Science ®Google Scholar
• Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett 2010;20:4511–4.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar